Aim: We represent variation of bilio-digestive stomy with "lost" protecting drainage during conventional palliative procedure of nonresectable tumors of periampullary region.

Materials And Methods: During the period 01.01.2008 -31.05.2008 in the Clinic of general and liver-pancreatic surgery-"Aleksandrovska" Hospital, Sofia, we applied modified technique for internal bilio-digestive prosthetic drain with "lost" drainage, protecting choledocho-duodenostomy in 12 patients with nonresectable tumors of periampullary region. Eight of them are males and 4--females, with age between 60-82 (average 64,5). In 8 patients we found nonresectable malignancy of the head of pancreas and in 4 nonresectable malignancy of distal part of the common bile duct.

Results: We follow the early postoperative results and postoperative period during tree months. We did not have insufficiency of the choledocho-duodenostomy and that afford early discharge of the patients. At the end of third month we haven't observed jaundice or other complications cause of obstruction of protecting drainage.

Conclusion: We consider that the technique is useful and appropriate when doing choledocho-duodenostomy cause of nonresectable periampullary neoplasms. The using of this technique don't increase the postoperative morbidity and improve early postoperative results.

Download full-text PDF

Source

Publication Analysis

Top Keywords

nonresectable tumors
12
tumors periampullary
12
technique internal
8
drainage conventional
8
conventional palliative
8
palliative procedure
8
procedure nonresectable
8
patients nonresectable
8
nonresectable malignancy
8
early postoperative
8

Similar Publications

Backgrounds/aims: Irreversible electroporation (IRE) may have a potential application as either a "back-up therapy" or for margin accentuation during trial dissection of locally advanced pancreatic cancer (LAPC). The aim of this report was to describe our experience with IRE in terms of its potential applications mentioned above.

Methods: A clinical policy to use IRE in LAPC patients undergoing exploratory surgery after neoadjuvant therapy (NAT) was initiated in 2017.

View Article and Find Full Text PDF

: To analyze the results of interstitial (IRT) high-dose-rate (HDR) brachytherapy (BT) in the primary treatment of patients with unresectable superior sulcus tumors (SST) combined with external beam radiotherapy (EBRT). : Between 2013 and 2023, seven patients with unresectable SST were treated with combined BT and EBRT with or without concomitant chemotherapy. The patients' median age was 64 years (range, 49-79 years) and median tumor volume was 146.

View Article and Find Full Text PDF

An updated review about the possibility of surveillance strategy in non-resected mucinous cystic neoplasms.

J Hepatobiliary Pancreat Sci

January 2025

Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.

After the World Health Organization established a precise definition of mucinous cystic neoplasm (MCN) in 2000, based on the presence of ovarian-type stroma, its clinical features became more apparent. Surgery for MCN, which primarily affects middle-aged women with long life expectancies, is likely to negatively impact the patient's quality of life. Although recent studies have reported a low proportion of advanced neoplasia among resected MCN (≤15%), many clinicians still recommend surgery for patients with presumed MCN without considering risk stratification for advanced neoplasia.

View Article and Find Full Text PDF

Background: Granulosa cell ovarian tumors (GCTs) are a rare neoplasia characterized by a pathognomonic mutation in the FOXL2 gene. In vitro studies have demonstrated an overactivation of hormone activity due to this alteration. Thus, we aimed to determine the activity of orteronel, a CYP17 inhibitor, in advanced disease.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!